Disease Information & Support


The Word:


Generic name Alemtuzumab
Pronunciation ah-lem-TOOZ-i-mab
Brand name(s), other common name(s) Campath®
Drug type  Monoclonal antibody
How the drug is given Intravenously (IV)

Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).

Side effects needing medical attention: Fever or chills; cough or hoarseness; back, lower back or side pain; painful or difficult urination; bleeding or bruising; black, tarry stools; blood in urine or stools; pinhead-sized red spots on skin; diarrhea; dizziness; faintness, or lightheadedness when getting up from a lying or sitting position; headache; itching, hives or rash; nausea and vomiting; pale skin; shortness of breath; sore throat; sores, ulcers or white spots on lips or in mouth, or swelling or inflammation of the mouth; sudden sweating; swollen glands; tightness in chest; troubled breathing after exertion; unusual tiredness or weakness; wheezing; acid or sour stomach; bone pain; burning, crawling, itching, numbness, prickling, "pins and needles," or tingling feelings; lack or loss of strength; loss of appetite; muscle aches; painful cold sores or blisters on lips, nose, eyes or genitals; sleeplessness; stomach discomfort, upset or pain; weight loss.


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Friday, October 12, 2012